Psyche Systems
Psyche Systems

HOPKINTON, Mass., August 29, 2023 (Newswire.com) - Psychē Systems, a leading provider of laboratory information software (LIS) solutions, today announced significant changes to its leadership team as part of its ongoing strategy to drive growth and enhance customer experience. This comes alongside the release of the company's brand-new website, reflecting the company's commitment to innovation and quality.

The strategic reshuffling of the leadership team underscores Psychē Systems' mission to foster positive change and growth within the organization. Ivy Cody has assumed the role of VP of Technical Operations, bringing her extensive experience and unique perspective to the team. The company also announced the appointment of Michelle Austin, Jason Froment, and Melissa Franklin to the Executive Leadership Team (Psychē Directions).

"We believe that these changes will bolster our efforts to deliver outstanding service and innovative solutions to our clients. Ivy, Michelle, Jason, and Melissa bring a wealth of knowledge and experience to their roles and will be instrumental in guiding Psychē Systems into its next phase of growth," said Psychē COO John Basile. 

Psychē Systems is also excited to announce the launch of its new website. The redesigned site offers a user-friendly experience with improved navigation and functionality while allowing customers to see the full product portfolio Psychē Systems can offer.

For more information about Psychē Systems and to view the new website, visit www.psychesystems.com.

About Psychē Systems

Psychē Systems is an industry-leading Laboratory Information System company founded by Bob Sage in 1976. Still 100% owned and operated by Mr. Sage, Psychē continues to raise the bar in the Anatomic Pathology and Molecular Diagnostics space.

Medicated

CEDAR RAPIDS, Iowa, August 29, 2023 (Newswire.com) - Organic lip care brand leader Eco Lips (ecolips.com/) is expanding their organic lip care brand to include the first-ever OTC-certified organic medicated lip balm to soothe and protect painful fever blisters and cold sores.

Eco Lips Medicated Lip Balm soothes and creates a barrier to protect sensitive lips without petroleum or alcohol. Uniquely formulated with natural, topical therapeutic ingredients like menthol, tea tree, lemon balm, echinacea, St. John's Wort, and licorice root to provide a cool soothing effect, which promotes relief of painful fever blisters and cold sores.

Eco Lips is excited to announce the company's premium medicated lip care product has launched in CVS stores across the USA.

Eco Lips Founder, Steve Shriver, is excited about the much-anticipated launch. He states, "The placement at CVS, the largest drugstore chain in the USA, is a major milestone for the product's retail rollout. The inclusion further establishes confidence in our products and meeting demand for this category with consumers."

According to the Centers for Disease Control and Prevention (CDC), 48% of people aged 14-49 years have HSV-1 infections. Cold sores are the main symptom of an HSV-1 infection. They usually form on or around the mouth but can also develop inside the nose or on the chin or cheek. The first symptoms of a cold sore include a tingling, itching, or burning sensation. Within around 48 hours, a sore will appear. It usually heals within 1-2 weeks.

Eco Lips Medicated Lip Balm is available at CVS stores nationwide as of August 2023. 

About Eco Lips

Founded in 2003, Eco Lips is the original organic lip balm. They manufacture the best USDA organic and Fair Trade Certified™ lip care products for the world using 100% renewable energy. Eco Lips products are Non-GMO Project Verified, Leaping Bunny Certified and gluten-free. Eco Lips is a certified B Corporation focused on the triple bottom line: people, planet and profits. Private label and contract manufacturing is also available. To learn more, visit ecolips.com/ or call 866-326-5477.

ORLANDO, Fla., August 28, 2023 (Newswire.com) - The Assistance Fund, an independent charitable patient assistance organization that helps patients and families facing high medical out-of-pocket costs, today announced the launch of a new financial assistance program for people living with idiopathic hypersomnia. The program is designed to help eligible individuals pay for their out-of-pocket medical expenses related to idiopathic hypersomnia, such as copays, health insurance premiums, and incidental medical expenses.

Idiopathic hypersomnia (IH) is a rare condition causing people to have difficulty staying awake during the day.^[1] Tiredness may begin at any time during the day and can severely disrupt normal activity. Many people living with IH sleep more than 11 hours a day and still do not feel rested.^[2]

"Most people living with idiopathic hypersomnia require treatment to perform the most basic, everyday tasks," said Danielle Vizcaino, President and CEO at The Assistance Fund. "Thanks to our generous donors, TAF's new Idiopathic Hypersomnia Financial Assistance Program will enable people living with this condition to lead healthier and more productive lives."

To learn more or determine eligibility for financial support, visit tafcares.org or call (855) 369-2728 to speak with a Patient Advocate.

A list of all the disease programs available from The Assistance Fund can be found on the website tafcares.org.

About The Assistance Fund

The Assistance Fund (TAF) is an independent charitable patient assistance organization that helps patients and families facing high medical out-of-pocket costs by providing financial assistance for their copayments, coinsurance, deductibles, and other health-related expenses. The Assistance Fund currently manages nearly 90 disease programs, each of which covers all the FDA-approved medications that treat a specific disease named in the disease program. Since its founding in 2009, TAF has helped nearly 180,000 children and adults access the treatment they need to stay healthy or manage a life-threatening, chronic or rare disease. To learn more about The Assistance Fund or for information on how to donate, please visit tafcares.org. 

^[1] National Center for Advancing Translational Sciences Genetic and Rare Diseases Information Center, National Institutes of Health, "Idiopathic hypersomnia," https://rarediseases.info.nih.gov/diseases/8737/idiopathic-hypersomnia, accessed May 2023.

^[2] Hypersomnia Foundation, "About Idiopathic Hypersomnia," accessed May 2023.